Volume 122, Issue 1 , Pages 133-138, July 2008
Use of multiple doses of epinephrine in food-induced anaphylaxis in children
Background
Food allergy is the most common cause of anaphylaxis outside the hospital setting.
Objective
We sought to determine the rate, circumstances, and risk factors for repeated doses of epinephrine in the treatment of food-induced anaphylaxis in children.
Methods
Anonymous questionnaires were distributed to families of children with food allergies during allergy outpatient visits to a food allergy referral center. Demographic information, allergy and reaction history, and details regarding the last 2 anaphylactic reactions requiring epinephrine were collected.
Results
A total of 413 questionnaires were analyzed. Seventy-eight children (median, 4.5 years of age; range, 0.5-17.5 years) reported 95 reactions for which epinephrine was administered. Two doses were administered in 12 (13%) and 3 doses in an additional 6 (6%) reactions treated with epinephrine. Peanut, tree nuts, and cow's milk were responsible for >75% of reactions requiring epinephrine. Patients receiving multiple doses of epinephrine more often had asthma (P = .027) than children receiving a single dose. The amount of food ingested or a delay in the initial administration of epinephrine were not risk factors for receiving multiple doses. The second dose of epinephrine was administered by a health care professional in 94% of reactions.
Conclusion
In this referral population of children and adolescents with multiple food allergies, 19% of food-induced anaphylactic reactions were treated with more than 1 dose of epinephrine. Prospective studies are necessary to identify risk factors for severe anaphylaxis and to establish rational guidelines for prescribing multiple epinephrine autoinjectors for children with food allergy.
Key words: Food allergy, autoinjector, self-injectable, epinephrine, children, anaphylaxis, food-induced anaphylaxis, peanut allergy, tree nut allergy, cow's milk allergy, milk allergy
Abbreviation used: EAI, Epinephrine autoinjector
K. M. Järvinen is supported in part by the 2007 American Academy of Allergy, Asthma & Immunology Third-Year Fellow-in-Training Research Award. S. H. Sicherer and H. A. Sampson are supported in part by grants from the National Institutes of Health, AI44236 and AI066738. A. Nowak-Wegrzyn is supported in part by a grant from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, AI059318.
Disclosure of potential conflict of interest: K. M. Järvinen has received research support from the American Academy of Allergy, Asthma & Immunology. S. H. Sicherer has consulting arrangements with the Food Allergy Initiative, has received research support from the National Institutes of Health, and has served as a member of the Food Allergy and Anaphylaxis Network and the American Academy of Pediatrics. H. A. Sampson has consulting arrangements with Allertein Therapeutics, has received research support from the National Institutes of Health and the Food Allergy Initiative, and has served as a member of the Food Allergy and Anaphylaxis Network. A. Nowak-Wegrzyn has received research support from the National Institutes of Health.
PII: S0091-6749(08)00775-6
doi:10.1016/j.jaci.2008.04.031
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 122, Issue 1 , Pages 133-138, July 2008
